Press Releases

Featured Press Releases

Announcing Investor Connect Plus: A LaunchBio x…

Accelerating Growth Through ConnectionsLaunchBio and the Biotechnology Innovation Organization (BIO) today announced the launch of Investor Connect Plus, an exclusive, BIO member-only investor access program designed for established, capital-ready…

Learn more

BIO Statement on Reintroduction of the PASTEUR Act

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance …

Learn more

BIO Statement on Passage of Bipartisan…

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement.“The passage of the Mikaela Naylon Give Kids a Chance Act is a bipartisan victory for children and…

Learn more

BIO Submits Comments on EPA’s Proposed Denial of Petitions for Rulemaking to Change the RFS Point of Obligation

February 22, 2017

In BIO’s view, granting the petitions to change the point of obligation would create unnecessary regulatory uncertainty and fail to further the statutory goals of the Renewable Fuel Standard (“RFS”) program.

Nominations Now Open for the BIO George Washington Carver Award for Innovation in Industrial Biotechnology

February 22, 2017

The ninth annual George Washington Carver Award will recognize an individual who has made a significant contribution to building the biobased economy by applying industrial biotechnology to create sustainable and environmentally…

BIO Submits Comments on EPA Renewables Enhancement and Growth Support Rule

February 16, 2017

The Biotechnology Innovation Organization (BIO) today submitted comments on the Environmental Protection Agency’s recently proposed Renewables Enhancement and Growth Support (REGS) Rule. BIO supports EPA’s ongoing efforts to improve the efficiency…

BIO Statement on National Academies’ Consensus Study on Human Gene Editing

February 14, 2017

Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement regarding the Consensus Study on Human Gene Editing, released today by the Human Gene Editing Initiative of the National Academies…

EU’s Anti-Science Comitology Reform Threatens Innovation

February 14, 2017

Washington, D.C. (February 14, 2017) – The European Commission announced today a proposal to revise its Comitology Regulation forcing policy decisions to individual EU member countries.

BIO Announces Gary Andres as the New Senior Executive Vice President of Public Affairs

February 14, 2017

Long-time Majority Staff Director of the House Energy and Commerce Committee Dr. Gary Andres joins BIO as Senior Executive Vice President of Public Affairs.

Registration Now Open for the 14th Annual BIO World Congress on Industrial Biotechnology

February 8, 2017

BIO announced registration and housing are now open for the 2017 World Congress on Industrial Biotechnology. The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal,…

BIO Statement on President Trump’s Comments Supporting Biopharmaceutical Competition and Innovation

January 31, 2017

Washington, DC (January 31, 2017) – BIO issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation:

BIO Statement on USDA and FDA Actions related to Pre-market Regulatory Oversight of Plant and Animal Organisms

January 18, 2017

The U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) published today four documents related to the pre-market regulatory oversight of a variety of biology-based agricultural tools, including genetically…

BIO’s Jim Greenwood Meets with India’s PM Modi

January 13, 2017

Delivers Message: India Must Protects Innovators’ Work Product

Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy.